Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

Johnson & Johnson - Optimising the personalisation of GU cancer care

The significance of BRCA1/2 mutations in mCRPC outcomes

Date

13 Sep 2024

Session

Johnson & Johnson - Optimising the personalisation of GU cancer care

Topics

Tumour Site

Prostate Cancer

Presenters

Elena Verzoni

Authors

E. Verzoni

Author affiliations

  • Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introduction

Presenter: Patrizia Giannatempo, Alison Birtle

Session: Johnson & Johnson - Optimising the personalisation of GU cancer care

Resources:

Webcast

Panel discussion

Presenter: Patrizia Giannatempo, Alison Birtle, Alejo Rodriguez-Vida, Elena Verzoni

Session: Johnson & Johnson - Optimising the personalisation of GU cancer care

Resources:

Webcast

FGFR testing: Why, how, when?

Presenter: Viktor Gruenwald

Session: Johnson & Johnson - Optimising the personalisation of GU cancer care

Resources:

Webcast

Summary and Close

Presenter: Patrizia Giannatempo, Alison Birtle

Session: Johnson & Johnson - Optimising the personalisation of GU cancer care

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.